1. The platelet-rich plasma lysate use in the treatment of persistent epithelial defects after keratoplasty
- Author
-
Nare P. Shakhbazyan, Anastasia M. Subbot, and Sergey V. Trufanov
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Surgery ,medicine.anatomical_structure ,Platelet-rich plasma ,Adjuvant therapy ,General Earth and Planetary Sciences ,Medicine ,Effective treatment ,Blood derivatives ,business ,Standard therapy ,Corneal transplantation ,General Environmental Science ,Corneal epithelium - Abstract
AIM:to evaluate the effectiveness of the platelet-rich plasma lysate (PRP lysate) use in the treatment of persistent epithelial defects (PED) after keratoplasty. MATERIALS AND METHODS:In the study, 60 patients with PED after keratoplasty were included. The 1st group (24 cases)included patients after keratoplasty with low risk of rejection, and the 2nd group 36 cases after keratoplasty with highrisk of rejection. Each group was divided into two subgroupscontrol subgroups 1a (cases 10) and 2a (cases 16), where patients received only standard postoperative therapy, and the main subgroups 1b (cases 14) and 2b (cases 20), in which PRP lysate was prescribed against the background of standard therapy, starting from the Day 15 post-op. As the criterion for effective treatment, complete persistent epithelialization after keratoplasty was considered. RESULTS:The effectiveness of the use of PRP lysate in the subgroup 1b was 85.7%, while complete epithelialization in the control subgroup 1a was recorded in 70%; in the subgroup 2b, complete epithelialization was observed in 55%, in the control subgroup 2ain 43.75%. CONCLUSION:The use of PRP lysate in the treatment of PED after corneal transplantation as an adjuvant therapy is effective and safe in both high and low risk keratoplasty. In the examined category of patients, treatment with blood derivatives increases the frequency and rate of complete epithelialization.
- Published
- 2021